Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · FY 2026

Arrowhead Pharmaceuticals FY 2026 Results: Net Loss of $724M, Loss Widens

Arrowhead Pharmaceuticals reported significant revenue from collaborations with Novartis ($89.0 million) and Madrigal ($25.0 million) in fiscal 2026, while total R&D expenses rose 22% to $739.1 million due to pipeline progression. A major one-time operating expense of $215.0 million was recorded for the acquisition of a Priority Review Voucher to accelerate the plozasiran sNDA.

FY 2026 at a glance · $ million · annual
MetricFY 2026FY 2025
Revenue450.8829.4
Profit before tax-723.951.5
Net income-724.2-1.6
EPS (diluted, $ a share)$-5.11$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-45.6%
Operating margin-156.9%
Source

10-K filed with the SEC, NASDAQ: ARWR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Arrowhead Pharmaceuticals, Inc.: key numbers

Share price
$44.21Close, Nov 16
Market cap
$6.25B
Shares outstanding
141.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Arrowhead Pharmaceuticals, Inc.

All →
4:02 PM ET 8-K
Financial Results

Arrowhead Pharmaceuticals Financial Results

Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.

Term
FY2026

“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”

Christopher Anzalone, Ph.D., President and CEO

“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”

Christopher Anzalone, Ph.D., President and CEO
7:30 AM ET 8-K
Loan & Debt

Arrowhead Pharmaceuticals $400M Debt Financing with Sixth Street Lending Partners

Arrowhead Pharmaceuticals refinanced its existing senior secured term loans by entering into a new $400 million Amended and Restated Financing Agreement with Sixth Street. The new facility significantly lowers borrowing costs from a 15% fixed rate to SOFR plus 5.50%, extends the maturity to November 2031, and eliminates previous requirements to sweep commercial revenue or milestone payments for debt repayment.

Value
$400M
Counterparty
Sixth Street Lending Partners
Term
5 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.